Tanew A, Radakovic-Fijan S, Schemper M, Hönigsmann H
Department of Dermatology, University of Vienna Medical School, Austria.
Arch Dermatol. 1999 May;135(5):519-24. doi: 10.1001/archderm.135.5.519.
To compare the therapeutic efficacy of narrowband (TL-01) UV-B phototherapy vs photochemotherapy (psoralen-UV-A [PUVA]) in patients with chronic plaque-type psoriasis.
Open, nonrandomized, intraindividually controlled paired comparison study.
Phototherapeutic unit in a university hospital.
Twenty-five patients with chronic plaque-type psoriasis.
Paired irradiations with threshold erythemogenic doses of narrowband UV-B and PUVA were given to the patients' dorsal aspect including the arms and legs. Treatment was performed 3 times weekly until complete or almost complete clearing with one or both regimens or over a maximum period of 18 exposures.
Assessment of the Psoriasis Area and Severity Index (PASI) in each half of the patient's dorsal aspect before and after treatment with the 2 regimens.
The median pretreatment PASI score of 16 (range, 6.2-23.4) was reduced by 84% to 2.5 (range, 0-12.6) by the narrowband UV-B treatment and by 89% to 1.8 (range, 0-8.2) by the PUVA treatment. Statistical analysis of these data showed a tendency for PUVA being superior to narrowband UV-B although the difference remained below the level of significance (P = .17). However, a clear effect of the pretreatment PASI score on the therapeutic outcome was found. Patients with higher baseline PASI scores responded significantly better to PUVA than to narrowband UV-B (P = .03).
Our data demonstrate that in many patients with plaque-type psoriasis, narrowband UV-B is comparably as effective as PUVA and, given the lack of photosensitizer-related adverse reactions and the possibly lower long-term cancer risk, can be considered as first-line treatment. Treatment with PUVA, on the other hand, remains the mainstay for patients with high PASI scores who do not respond or whose psoriasis cannot be controlled adequately by narrowband UV-B.
比较窄谱(TL-01)UV-B光疗与光化学疗法(补骨脂素-UV-A[PUVA])治疗慢性斑块型银屑病患者的疗效。
开放、非随机、个体内对照配对比较研究。
大学医院的光疗科。
25例慢性斑块型银屑病患者。
对患者包括手臂和腿部的背部进行窄谱UV-B和PUVA的阈红斑剂量配对照射。每周治疗3次,直至两种治疗方案之一完全或几乎完全清除皮损,或最长照射18次。
用两种治疗方案治疗前后,评估患者背部每一半的银屑病面积和严重程度指数(PASI)。
窄谱UV-B治疗使治疗前PASI中位数评分16(范围6.2 - 23.4)降低84%至2.5(范围0 - 12.6),PUVA治疗使其降低89%至1.8(范围0 - 8.2)。对这些数据的统计分析显示,PUVA有优于窄谱UV-B的趋势,尽管差异未达到显著水平(P = 0.17)。然而,发现治疗前PASI评分对治疗结果有明显影响。基线PASI评分较高的患者对PUVA的反应明显优于窄谱UV-B(P = 0.03)。
我们的数据表明,在许多斑块型银屑病患者中,窄谱UV-B与PUVA疗效相当,且由于缺乏与光敏剂相关的不良反应以及可能较低的长期癌症风险,可被视为一线治疗方法。另一方面,对于PASI评分高、对窄谱UV-B无反应或银屑病无法通过窄谱UV-B充分控制的患者,PUVA治疗仍是主要治疗方法。